Patient has overt, uncontrollable, life-threatening bleeding or patient requires emergent surgery/procedure and current bleeding level could become life-threatening during surgery/procedure.
Confirmed or highly suspected dabigatran use within the last 48hrs if creatinine clearance > 50 mL/min or within the last 5 days if creatinine clearance < 50 mL/min.
Exclusion Criteria: (any one of the following)
Absence of clinical signs of active major bleeding or hemodynamic instability
Minor bleeding that can be managed with supportive care. (half-life of dabigatran is ≈ 12-17 hrs)
Elective surgery/invasive procedure
Surgery/invasive procedure in which the risk of uncontrolled or unmanageable bleeding is low.
Hereditary Fructose Intolerance (Idarucizumab contains 4 g sorbitol)
Idarucizumab is indicated for patients treated with dabigatran (Pradaxa) when reversal of the anticoagulant effects of dabigatran is needed.
*** Idarucizumab will not reverse the effects of other anticoagulants***
***Idarucizumab can be given to patients who have received other supportive measures
(fresh frozen plasma, prothrombin complex concentrates, Factor VII)***
Inclusion Criteria: (must meet all)
Exclusion Criteria: (any one of the following)
Reviewed: 17 Nov 2015 (Praxbind)
Updated: April 2022 (Praxbind)